A Phase 1/2 interventional study of allo-APZ2-EB in Recessive Dystrophic Epidermolysis Bullosa, sponsored by RHEACELL GmbH & Co. KG. Completed at 6 sites in 5 countries. Open to participants aged 0 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-10-07.
Sponsored by RHEACELL GmbH & Co. KG · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this clinical trial is to investigate the efficacy (by monitoring overall improvement of EB symptoms) and safety (by monitoring adverse events) of three doses of allo-APZ2-EB administered intravenously to patients with recessive dystrophic epidermolysis bullosa (RDEB).
This is an interventional, single arm, non-randomized, open label, phase I/IIa clinical trial to investigate the efficacy and safety of the IMP allo-APZ2-EB in patients with RDEB.
Patients will undergo treatment with the IMP (three repeated intravenous applications) and will be followed up for efficacy for 12 weeks. To assess long-term safety of allo-APZ2-EB one follow-up visit at Month 12 and one follow-up visit at Month 24 post IMP applications is included.
Determination of the EB linked symptoms and quality of life will be assessed by using the EBDASI score, the iscorEB, the change in pain and itch perception, and patient's quality of life in EB. The wound healing process will be documented by photography.
79 studies on the registry are indexed under Epidermolysis Bullosa Dystrophica; 22 are open to participants now.
This study's enrollment of 16 is above the median of 9 across 56 interventional studies indexed under Epidermolysis Bullosa Dystrophica.
Browse Epidermolysis Bullosa Dystrophica studies →RHEACELL GmbH & Co. KG is the lead sponsor of 11 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Staggered design for patient enrollment:
US only:
Patient is eligible to participate in this clinical trial based on general health condition assessed by specific lab values (Hematology: >1000/mm3 and count >150,000/mcL; Coagulation: PT and \<2x the for age; Hepatic: and ALT \<2x the upper limit of normal for age; Renal: Creatinine \<2x the upper limit of normal for age; Pulmonary: Oxygen saturation >92% on room air and without supplemental oxygen requirement);
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
intravenous infusion, three doses of allo-APZ2-EB (2 x 10\^6 cells/kg)
Biological: allo-APZ2-EB
intravenous infusion of allo-APZ2-EB
Also known as: allogeneic ABCB5-positive mesenchymal stem cells
Overall improvement of EB symptoms after 12 weeks (measured by percentage change of a patient's EBDASI score), score), or last available post-baseline measurement if the Week 12 measurement is missing
EBDASI: epidermolysis bullosa disease activity and scarring index; measured in percentage change to baseline score
Time frame: Week 12 post baseline, or last available post-baseline measurement if the Week 12 measurement is missing (last observation carried forward [LOCF])
Assessment of adverse event (AE) occurrence
All AEs occurring during the clinical trial will be registered, documented and evaluated.
Time frame: Up to 24 months
Overall improvement of EB symptoms after 12 weeks (measured by percentage change of a patient's EBDASI score)
EBDASI: epidermolysis bullosa disease activity and scarring index; measured in percentage change to baseline score
Time frame: between baseline and week 12 post baseline (without LOCF)
Overall improvement of EB symptoms after 12 weeks (measured by percentage change of patient's iscorEB), or last available post-baseline measurement if the Week 12 measurement is missing
iscorEB: instrument for scoring clinical outcome of research for epidermolysis bullosa; measured in percentage change to baseline score
Time frame: Week 12 post baseline, or last available post-baseline measurement if the Week 12 measurement is missing (LOCF);
Overall improvement of EB symptoms after 12 weeks (measured by percentage change of patient's iscorEB)
iscorEB: instrument for scoring clinical outcome of research for epidermolysis bullosa; measured in percentage change to baseline score
Time frame: between baseline and week 12 post baseline (without LOCF)
Overall improvement of EB symptoms at Day 17 (measured by percentage change of a patient's EBDASI score)
EBDASI: epidermolysis bullosa disease activity and scarring index; measured in percentage change to baseline score
Time frame: between baseline and day 17 post baseline
Overall improvement of EB symptoms at Day 17 (measured by percentage change of a patient's iscorEB)
iscorEB: instrument for scoring clinical outcome of research for epidermolysis bullosa; measured in percentage change to baseline score
Time frame: between baseline and day 17 post baseline
Overall improvement of EB symptoms at Day 35 (measured by percentage change of a patient's EBDASI score)
EBDASI: epidermolysis bullosa disease activity and scarring index; measured in percentage change to baseline score
Time frame: between baseline and day 35 post baseline
Overall improvement of EB symptoms at Day 35 (measured by percentage change of a patient's iscorEB)
iscorEB: instrument for scoring clinical outcome of research for epidermolysis bullosa; measured in percentage change to baseline score
Time frame: between baseline and day 35 post baseline
Inflammation (measured by panel of inflammation markers)
A panel of inflammation markers will be measured and evaluated.
Time frame: between baseline and day 17, day 35 and week 12 post baseline
Pain assessment as per NRS
Pain assessment as per numerical rating scale (NRS) will be evaluated.
Time frame: between baseline and day 17, day 35 and week 12 post baseline
Itch assessment as per NRS
Itch assessment as per numerical rating scale (NRS) will be evaluated.
Time frame: between baseline and day 17, day 35 and week 12 post baseline
Differences in patient's quality of life in EB
Assessment of quality of life data using an EB-specific quality of life questionnaire
Time frame: between baseline and day 17, day 35 and week 12 post baseline
Physical examination until Week 12;
A full physical examination will be performed and abnormal physical examination results will be evaluated and reported as AEs.
Time frame: At Screening, baseline, day 17, day 35 and week 12
Vital signs: Body temperature until Week 12;
Body temperature will be evaluated at Screening, baseline, day 17, day 35 and week 12
Time frame: At Screening, baseline, day 17, day 35 and week 12
Vital signs: Blood pressure until Week 12;
Blood pressure will be evaluated at Screening, baseline, day 17, day 35 and week 12
Time frame: At Screening, baseline, day 17, day 35 and week 12
Vital signs: Heart rate until Week 12;
Heart rate will be evaluated at Screening, baseline, day 17, day 35 and week 12
Time frame: At Screening, baseline, day 17, day 35 and week 12
Overall survival at month 24
Time frame: month 24 post baseline
Plan to share: Undecided
Ran from Feb 2019 to primary completion in Nov 2021, 33 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Epidermolysis Bullosa Dystrophica →
RHEACELL GmbH & Co. KG